Back to Blog
MoCRANovember 16, 2026

Beyond the Lab: Building a Defensible Safety Substantiation File

Under the Modernization of Cosmetics Regulation Act (MoCRA), enacted in December 2022 and now fully in force, every cosmetic product sold in the United States must have "adequate substantiation" of safety before it reaches a shelf or a shopping cart. For indie and startup beauty brands, this requirement can feel vague and intimidating—especially because MoCRA does not hand founders a checklist of required laboratory tests. That ambiguity is intentional, and understanding why is the key to building a safety file that will actually hold up to FDA scrutiny, litigation discovery, or an insurance underwriter's due diligence.

The MoCRA Mandate: Safety Substantiation, Not a Checklist

MoCRA directs the "responsible person" for a cosmetic—generally the manufacturer, packer, or distributor listed on the label—to maintain records supporting the safety of each product. The statute defines "safety" as the product being unlikely to cause injury when used as labeled or under customary conditions of use, including reasonably foreseeable misuse.

Notably absent from MoCRA is any list of mandatory assays, patch tests, or stability protocols. Congress and the FDA deliberately avoided a one-size-fits-all testing regime because cosmetic formulations, delivery systems, and risk profiles vary too widely for a single checklist to make scientific sense. Instead, the law shifts the burden to the brand: you must assemble and curate a body of evidence sufficient to justify your own safety conclusion.

What "Adequate Substantiation" Actually Means

FDA guidance describes adequate substantiation as "tests, studies, research, analyses, or other evidence or information that is sufficient to support a reasonable certainty that a cosmetic product is safe." This is a flexible, evidence-based standard—closer to a civil "preponderance" analysis than a rigid regulatory gate.

In practice, adequate substantiation can be built from a combination of:

Need a legal review of a cosmetic product, label, or FDA matter? Tell us about the product.

Request a MoCRA Compliance Review
  • Ingredient-level safety data already published by the Cosmetic Ingredient Review (CIR) panel or peer-reviewed literature
  • Supplier Certificates of Analysis and raw material safety data sheets
  • Historical use data showing an ingredient's long safety record at specified concentrations
  • Toxicological risk assessments performed by a qualified chemist or toxicologist
  • Microbial and preservative efficacy testing appropriate to the product's water activity and packaging
  • Stability testing demonstrating the formula remains safe and effective through its intended shelf life
  • Consumer-use or clinical testing where claims or novel ingredients warrant it

No single document proves safety. The file is a mosaic, and FDA inspectors will evaluate whether the pieces logically and scientifically fit together.

Cosmetics vs. Drugs: Why the Distinction Matters

A safety file cannot be divorced from classification. FDA regulates cosmetics and drugs under different legal frameworks, and the line between them is drawn by intended use, not ingredient list. A product is a drug if it is intended to diagnose, cure, mitigate, treat, or prevent disease, or to affect the structure or function of the body.

This matters enormously for substantiation strategy. A moisturizer marketed to "hydrate and smooth skin" is a cosmetic claim supported by cosmetic-level substantiation. The same formula marketed to "treat eczema" or "reduce inflammation" crosses into drug territory, triggering FDA's much more rigorous New Drug Application or OTC monograph requirements—an entirely different, costlier regulatory pathway that most indie brands are not equipped to pursue.

Marketing Claims Can Turn Your Cosmetic Into a Drug

Founders frequently underestimate how marketing copy, not formulation, drives regulatory risk. Words like "anti-aging," "heals," "repairs cellular damage," or "clinically proven to reduce wrinkles" can be read by FDA as implied drug claims, regardless of how the product is labeled on the ingredient panel.

Your safety substantiation file should be built in lockstep with your claims strategy. If your marketing team wants to say a serum "reduces the appearance of fine lines," your file needs performance data to back the claim and your legal team needs to confirm the claim stays on the cosmetic side of the line. Claims substantiation and safety substantiation are related but distinct obligations—both must be documented, and both should be reviewed before launch, not after a complaint or warning letter arrives.

Building the File: A Practical Roadmap for Indie Brands

For founders operating without an in-house regulatory department, a disciplined but lean process works best:

  • Start with ingredient dossiers. Pull CIR findings, published toxicology, and supplier documentation for every ingredient before formulation is finalized.
  • Commission a risk assessment. A credentialed cosmetic chemist or toxicologist can translate raw ingredient data into a product-specific safety opinion—often the single most persuasive document in a MoCRA file.
  • Test for what matters. Preservative efficacy and microbial testing are essential for water-based formulas; stability testing matters for anything with active or unstable ingredients; patch testing matters for products marketed as hypoallergenic or suitable for sensitive skin.
  • Document customary use. Define how consumers will actually use the product—frequency, application area, likely misuse—and show your substantiation accounts for that reality.
  • Create a living file, not a launch-day binder. Safety substantiation should be revisited whenever you reformulate, resource an ingredient, or expand claims.

Record Retention and FDA Access

MoCRA requires responsible persons to maintain safety substantiation records and make them available to FDA within a specified timeframe upon request—generally understood to be prompt production once requested, not an open-ended negotiation. Brands should keep organized, dated files (digital is fine) that a regulator or outside counsel could review without needing a translator to understand the brand's internal shorthand.

Common Pitfalls That Undermine a Safety File

  • Relying solely on supplier assurances without independent verification
  • Treating ingredient safety data as a substitute for finished-product testing
  • Failing to update the file after reformulation
  • Allowing marketing claims to outpace the underlying science
  • Storing substantiation records informally, making timely FDA production difficult

Next Steps for Founders

MoCRA rewards brands that think like scientists and lawyers simultaneously. Before your next launch, audit your ingredient list, align your claims with your evidence, and assemble a file that could survive both an FDA inquiry and a plaintiff's attorney's discovery request. Treating safety substantiation as a strategic asset—rather than a compliance afterthought—is what separates indie brands built to last from those built to be shut down by a warning letter.

This article is for informational purposes only and does not constitute legal advice. Contact our office for guidance specific to your situation.

Tell me what’s happening.

Share a brief summary so I can review it and reply personally.

I respond personally within 48 hours. If I can help, we’ll set up a short call.

Prefer to talk? Book a call

Please don’t include confidential information. Submitting this form doesn’t create an attorney-client relationship.

Related Services